Investigation of Ki-67 and Clinical Outcome in Feline Nasal Adenocarcinoma Treated Using Hypofractionated Radiotherapy

Premkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong · 2024

Read Investigation of Ki-67 and Clinical Outcome in Feline Nasal Adenocarcinoma Treated Using Hypofractionated Radiotherapy by Premkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11672515.txt.

Description

Premkamon Aonta and co-authors test a cell-growth marker in cats with nose cancer in this 2024 study. Nineteen cats with nasal adenocarcinoma received a compressed course of radiation. The marker, Ki-67, flags cells that are actively dividing, and it forecasts outcomes in human cancers.

Median survival for the group was 550 days. Cats whose tumors shrank lived far longer than those whose did not. Against expectation, cats with high Ki-67 lived longer than cats with low Ki-67, roughly a thousand days against under a year. White cell counts fell after treatment but did not track survival. The authors suggest Ki-67 may help forecast this cancer in cats, pending larger studies.

Catalog record

CREATORPremkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11672515

Browse the full library · About the Tower of Babel